OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study
Michael E. Wechsler, Linda B. Ford, Jorge Máspero, et al.
The Lancet Respiratory Medicine (2021) Vol. 10, Iss. 1, pp. 11-25
Open Access | Times Cited: 164
Michael E. Wechsler, Linda B. Ford, Jorge Máspero, et al.
The Lancet Respiratory Medicine (2021) Vol. 10, Iss. 1, pp. 11-25
Open Access | Times Cited: 164
Showing 26-50 of 164 citing articles:
Dupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe Asthma
Lawrence Sher, Michael E. Wechsler, Klaus F. Rabe, et al.
CHEST Journal (2022) Vol. 162, Iss. 1, pp. 46-55
Closed Access | Times Cited: 30
Lawrence Sher, Michael E. Wechsler, Klaus F. Rabe, et al.
CHEST Journal (2022) Vol. 162, Iss. 1, pp. 46-55
Closed Access | Times Cited: 30
Real-World Effectiveness of Dupilumab for Patients with Severe Asthma: A Retrospective Study
Takanori Numata, Jun Araya, Hanae Miyagawa, et al.
Journal of Asthma and Allergy (2022) Vol. Volume 15, pp. 395-405
Open Access | Times Cited: 30
Takanori Numata, Jun Araya, Hanae Miyagawa, et al.
Journal of Asthma and Allergy (2022) Vol. Volume 15, pp. 395-405
Open Access | Times Cited: 30
IgG4-related disease administered dupilumab: case series and review of the literature
Masatoshi Kanda, Ryuta Kamekura, M. Sugawara, et al.
RMD Open (2023) Vol. 9, Iss. 1, pp. e003026-e003026
Open Access | Times Cited: 22
Masatoshi Kanda, Ryuta Kamekura, M. Sugawara, et al.
RMD Open (2023) Vol. 9, Iss. 1, pp. e003026-e003026
Open Access | Times Cited: 22
Eosinophilic granulomatosis with polyangiitis developed after dupilumab administration in patients with eosinophilic chronic rhinosinusitis and asthma: a case report
Isao Suzaki, Akihiko Tanaka, Ryo Yanai, et al.
BMC Pulmonary Medicine (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 21
Isao Suzaki, Akihiko Tanaka, Ryo Yanai, et al.
BMC Pulmonary Medicine (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 21
Eosinophils—from cradle to grave
Miloš Jeseňák, Zuzana Diamant, Dagmar Simon, et al.
Allergy (2023) Vol. 78, Iss. 12, pp. 3077-3102
Open Access | Times Cited: 18
Miloš Jeseňák, Zuzana Diamant, Dagmar Simon, et al.
Allergy (2023) Vol. 78, Iss. 12, pp. 3077-3102
Open Access | Times Cited: 18
Biologic Therapies for Asthma and Allergic Disease: Past, Present, and Future
Fernando Ramírez-Jiménez, Gandhi F. Pavón-Romero, Juancarlos Manuel Velásquez-Rodríguez, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 2, pp. 270-270
Open Access | Times Cited: 17
Fernando Ramírez-Jiménez, Gandhi F. Pavón-Romero, Juancarlos Manuel Velásquez-Rodríguez, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 2, pp. 270-270
Open Access | Times Cited: 17
Safety of dupilumab in T2 airways conditions: focus on eosinophilia across trials and real-life evidence
Marco Caminati, Claudio Micheletto, Francesca Norelli, et al.
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 1-2, pp. 15-23
Closed Access | Times Cited: 7
Marco Caminati, Claudio Micheletto, Francesca Norelli, et al.
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 1-2, pp. 15-23
Closed Access | Times Cited: 7
Precision medicine for severe asthma – Biological targeted therapy
Bingqing Sun, Kunlu Shen, Ruiheng Zhao, et al.
International Immunopharmacology (2024) Vol. 134, pp. 112189-112189
Open Access | Times Cited: 6
Bingqing Sun, Kunlu Shen, Ruiheng Zhao, et al.
International Immunopharmacology (2024) Vol. 134, pp. 112189-112189
Open Access | Times Cited: 6
Real‐world data show sustained therapeutic effects of dupilumab in chronic rhinosinusitis with nasal polyps (CRSwNP ) over 3 years
Patrick Huber, Ulrike Förster‐Ruhrmann, Heidi Olze, et al.
Allergy (2024) Vol. 79, Iss. 11, pp. 3108-3117
Open Access | Times Cited: 6
Patrick Huber, Ulrike Förster‐Ruhrmann, Heidi Olze, et al.
Allergy (2024) Vol. 79, Iss. 11, pp. 3108-3117
Open Access | Times Cited: 6
Documento de consenso de asma grave en adultos. Actualización 2022
Francisco Javier Álvarez Gutiérrez, Marina Blanco–Aparicio, Francisco Casas Maldonado, et al.
Open Respiratory Archives (2022) Vol. 4, Iss. 3, pp. 100192-100192
Open Access | Times Cited: 23
Francisco Javier Álvarez Gutiérrez, Marina Blanco–Aparicio, Francisco Casas Maldonado, et al.
Open Respiratory Archives (2022) Vol. 4, Iss. 3, pp. 100192-100192
Open Access | Times Cited: 23
The Role of Eosinophil-Derived Neurotoxin and Vascular Endothelial Growth Factor in the Pathogenesis of Eosinophilic Asthma
Maciej Tota, Julia Łacwik, Julia Laska, et al.
Cells (2023) Vol. 12, Iss. 9, pp. 1326-1326
Open Access | Times Cited: 16
Maciej Tota, Julia Łacwik, Julia Laska, et al.
Cells (2023) Vol. 12, Iss. 9, pp. 1326-1326
Open Access | Times Cited: 16
Brazilian guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps ‒ 2024 update
Wilma Terezinha Anselmo‐Lima, Fabrizio Ricci Romano, Edwin Tamashiro, et al.
Brazilian Journal of Otorhinolaryngology (2024) Vol. 90, Iss. 3, pp. 101394-101394
Open Access | Times Cited: 5
Wilma Terezinha Anselmo‐Lima, Fabrizio Ricci Romano, Edwin Tamashiro, et al.
Brazilian Journal of Otorhinolaryngology (2024) Vol. 90, Iss. 3, pp. 101394-101394
Open Access | Times Cited: 5
Upadacitinib improves symptoms of concomitant allergic rhinitis or allergic asthma in patients with severe atopic dermatitis: A 16‐week multicentre retrospective study
Luigi Gargiulo, Luciano Ibba, Francesco Piscazzi, et al.
Journal of the European Academy of Dermatology and Venereology (2024) Vol. 38, Iss. 9
Closed Access | Times Cited: 5
Luigi Gargiulo, Luciano Ibba, Francesco Piscazzi, et al.
Journal of the European Academy of Dermatology and Venereology (2024) Vol. 38, Iss. 9
Closed Access | Times Cited: 5
Novel Biological Therapies for Severe Asthma Endotypes
Corrado Pelaia, Giulia Pelaia, Claudia Crimi, et al.
Biomedicines (2022) Vol. 10, Iss. 5, pp. 1064-1064
Open Access | Times Cited: 21
Corrado Pelaia, Giulia Pelaia, Claudia Crimi, et al.
Biomedicines (2022) Vol. 10, Iss. 5, pp. 1064-1064
Open Access | Times Cited: 21
Real-life effectiveness of dupilumab in patients with mild to moderate bronchial asthma comorbid with CRSwNP
Shunsuke Minagawa, Jun Araya, Naoaki Watanabe, et al.
BMC Pulmonary Medicine (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 21
Shunsuke Minagawa, Jun Araya, Naoaki Watanabe, et al.
BMC Pulmonary Medicine (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 21
Unanswered questions on the use of biologics in pediatric asthma
Antonio Nieto, Zeinab A. El-Sayed, René Maximiliano Gómez, et al.
World Allergy Organization Journal (2023) Vol. 16, Iss. 11, pp. 100837-100837
Open Access | Times Cited: 11
Antonio Nieto, Zeinab A. El-Sayed, René Maximiliano Gómez, et al.
World Allergy Organization Journal (2023) Vol. 16, Iss. 11, pp. 100837-100837
Open Access | Times Cited: 11
Dupilumab sustains lung function improvements in patients with moderate-to-severe asthma
Alberto Papi, Mario Castro, Jonathan Corren, et al.
Respiratory Medicine (2024), pp. 107535-107535
Open Access | Times Cited: 4
Alberto Papi, Mario Castro, Jonathan Corren, et al.
Respiratory Medicine (2024), pp. 107535-107535
Open Access | Times Cited: 4
Postmarketing Analysis of Eosinophilic Adverse Reactions in the use of Biologic Therapies for Type 2 Inflammatory Conditions
Dafna Gershnabel Milk, Kent Lam, Joseph K. Han
American Journal of Rhinology and Allergy (2024)
Closed Access | Times Cited: 4
Dafna Gershnabel Milk, Kent Lam, Joseph K. Han
American Journal of Rhinology and Allergy (2024)
Closed Access | Times Cited: 4
Biologics in severe asthma: a state-of-the-art review
Bishal Gyawali, Steve N. Georas, Sandhya Khurana
European Respiratory Review (2025) Vol. 34, Iss. 175, pp. 240088-240088
Open Access
Bishal Gyawali, Steve N. Georas, Sandhya Khurana
European Respiratory Review (2025) Vol. 34, Iss. 175, pp. 240088-240088
Open Access
Eosinophilic esophagitis in the “atopic march”: dupilumab as an “umbrella” strategy for multiple coexisting atopic diseases
Nicola Lutzu, Agnese Favale, M. Demurtas, et al.
Frontiers in Medicine (2025) Vol. 11
Open Access
Nicola Lutzu, Agnese Favale, M. Demurtas, et al.
Frontiers in Medicine (2025) Vol. 11
Open Access
Efficacy and Safety of Dupilumab Across Different Th2-Type-Mediated Diseases: A Real-Life Preliminary Experience
Ciro Romano, Domenico Cozzolino, Maria Elena Corona, et al.
Biologics (2025) Vol. 5, Iss. 1, pp. 3-3
Open Access
Ciro Romano, Domenico Cozzolino, Maria Elena Corona, et al.
Biologics (2025) Vol. 5, Iss. 1, pp. 3-3
Open Access
Small airways dysfunction in severe asthma: Current treatment approaches and future directions
Nishan Deng, Yunyan Xianyu, Yaqing Xu, et al.
Journal of the Formosan Medical Association (2025)
Open Access
Nishan Deng, Yunyan Xianyu, Yaqing Xu, et al.
Journal of the Formosan Medical Association (2025)
Open Access
Dupilumab Efficacy and Safety in Patients With Persistent Asthma: Asia–Pacific Region
Qingling Zhang, Nanshan Zhong, Sahajal Dhooria, et al.
Clinical & Experimental Allergy (2025)
Open Access
Qingling Zhang, Nanshan Zhong, Sahajal Dhooria, et al.
Clinical & Experimental Allergy (2025)
Open Access
Hypereosinophilia management in patients with type 2 chronic rhinosinusitis treated with dupilumab: preliminary results
Alessandro Vinciguerra, Andrea Rampi, Mona‐Rita Yacoub, et al.
European Archives of Oto-Rhino-Laryngology (2022) Vol. 279, Iss. 11, pp. 5231-5238
Closed Access | Times Cited: 17
Alessandro Vinciguerra, Andrea Rampi, Mona‐Rita Yacoub, et al.
European Archives of Oto-Rhino-Laryngology (2022) Vol. 279, Iss. 11, pp. 5231-5238
Closed Access | Times Cited: 17
Long-Term Efficacy of Dupilumab for Eosinophilic Chronic Rhinosinusitis
Yasuhiro Tsunemi, Tsuguhisa Nakayama, Takashi Kashiwagi, et al.
American Journal of Rhinology and Allergy (2023) Vol. 38, Iss. 1, pp. 14-22
Closed Access | Times Cited: 10
Yasuhiro Tsunemi, Tsuguhisa Nakayama, Takashi Kashiwagi, et al.
American Journal of Rhinology and Allergy (2023) Vol. 38, Iss. 1, pp. 14-22
Closed Access | Times Cited: 10
